Drugs / CSCJC3456
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06717750 | Feb 2025 → Jun 2027 expected | cancer | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSCJC3456 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06717750 ↗ |
| Action | Inhibit | “CSCJC3456 is a multi-target tyrosine kinase inhibitor” NCT06717750 ↗ |
| Route | Oral | “Oral CSCJC3456 Tablets” NCT06717750 ↗ |